The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market’s Market Value Anticipated To Evolve From 2026 To 2030?
The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market size has seen swift expansion in recent years. Its value is anticipated to rise from $54.73 billion in 2025 to $60.7 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.9%. This historical growth can be attributed to factors such as the restricted availability of specialized peptide API manufacturers, a reliance on in-house peptide production, an expanding range of peptide therapeutics in development, increasing demands for regulatory compliance, and the utilization of basic chemical synthesis methods.
The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $90.76 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.6%. This projected growth stems from various factors, including advancements in custom peptide synthesis technologies, the broadening of commercial-scale GMP manufacturing, increased reliance on outsourcing to CROs and SMEs, the evolution of lifecycle management and process optimization strategies, and a growing need for clinical and preclinical peptide API manufacturing. Key trends expected during this period involve an increase in outsourcing of peptide API manufacturing to specialized contract manufacturers, a rise in GMP-grade production for both clinical and commercial supply, surging demand for custom peptide synthesis and purification services, the expansion of peptide therapeutics pipelines within pharmaceutical firms, and a strong emphasis on optimizing processes and managing the lifecycle of peptide APIs.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25876&type=smp
What Important Drivers Are Powering The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Growth?
The expansion of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market is anticipated to be driven by increasing drug development and manufacturing activities. These activities encompass the intensified endeavors of pharmaceutical and biopharmaceutical companies in researching, developing, and producing novel medications. The surge in these operations primarily stems from the rising global demand for innovative and potent therapeutics, compelling companies to broaden their development portfolios and accelerate production schedules. A pharmaceutical CDMO supports drug development through the formulation and optimization of dosage forms, conducting stability testing, and ensuring adherence to regulatory standards. It further oversees scale-up procedures and production, facilitating quicker and more economical product introductions. For example, in June 2023, figures from the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry in Europe, indicated that the total pharmaceutical production in Europe reached $422,803 million (€390,000 million) in 2023, an increase from $393,857 million (€363,300 million) in 2022. Consequently, the heightened pace of drug development and manufacturing activities is fueling the expansion of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market.
How Are Different Segment Groups Identified Within The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?
The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market covered in this report is segmented –
1) By Dosage Form: Oral Solids, Oral Liquids, Injectables, Topicals, Inhalation Products, Transdermal And Patches, Other Dosage Forms
2) By Therapeutic Area: Oncology, Cardiology, Central Nervous System, Gastroenterology, Infectious Diseases, Endocrinology
3) By End-User: Pharmaceutical Companies, Biopharmaceutical Companies, Other End-Users
Subsegments:
1) By Oral Solids: Tablets, Capsules, Granules, Powders, Modified-Release Formulations
2) By Oral Liquids: Syrups, Suspensions, Solutions, Emulsions, Elixirs
3) By Injectables: Vials, Ampoules, Prefilled Syringes, Lyophilized Injections, Injectable Emulsions
4) By Topicals: Creams, Ointments, Gels, Lotions, Foams,
5) By Inhalation Products: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizer Solutions, Nasal Sprays, Inhalation Capsules
6) By Transdermal And Patches: Matrix Patches, Reservoir Patches, Drug-In-Adhesive Patches, Microneedle Patches, Iontophoretic Patches
7) By Other Dosage Forms: Suppositories, Ophthalmic Preparations, Buccal Tablets, Sublingual Tablets, Implants
Which Trends Are Supporting The Evolution Of The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?
Leading companies operating in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market are concentrating on creating sophisticated solutions, specifically biologic formulation platforms, to improve drug stability and expedite the market entry of intricate biologic treatments. These platforms are dedicated systems engineered for the purpose of generating stable and effective formulations for biologic medications. They meticulously adjust components like pH, excipients, and administration techniques, thereby boosting stability, bioavailability, and safety throughout a product’s lifespan. An example is WuXi Biologics, a China-based contract research, development, and manufacturing organization, which introduced WuXiHigh 2.0, an advanced high-concentration formulation platform, in June 2025. This cutting-edge platform facilitates biologic formulations reaching protein concentrations of up to 230 mg/mL, which exceeds the Food and Drug Administration’s current maximum approval of 200 mg/mL. Simultaneously, it achieves a viscosity reduction of up to 90% by utilizing unique excipient blends and high-throughput instruments. It tackles significant hurdles in creating high-concentration biologics, including viscosity and aggregation. Furthermore, it is engineered to enhance injection efficiency, patient adherence, and manufacturing results throughout both clinical and commercial phases.
Which Firms Are Competing In The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?
Major companies operating in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market are Thermo Fisher Scientific Inc., Lonza Group, Catalent Inc., WuXi Biologics, Samsung Biologics, Recipharm AB, Siegfried Holding AG, Evonik Industries AG, Almac Group, Aenova Group, Piramal Pharma Limited, Cambrex, Jubilant Pharmova Limited, CordenPharma, Altasciences, Hovione, Aurigene Pharmaceutical Services Ltd., DPT Laboratories Ltd., CARBOGEN AMCIS, Biopharma Group, LGM Pharma, Aarti Pharmalabs Limited.
Access The Complete Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Report:
Which Region Stands As The Largest Contributor To The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?
Asia-Pacific was the largest region in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=25876&type=smp
Browse Through More Reports Similar to the Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market 2026, By The Business Research Company
Pharmaceutical Contract Developments And Manufacturing Organization Cmo Market Report 2026
Topical Drugs Contract Development And Manufacturing Organization Cdmo Market Report 2026
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization Cdmo Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model